Equities Analysts Offer Predictions for NMRA FY2029 Earnings

Neumora Therapeutics, Inc. (NASDAQ:NMRA) – Investment analysts at William Blair issued their FY2029 earnings per share estimates for shares of Neumora Therapeutics in a research report issued on Thursday, January 2nd. William Blair analyst M. Minter forecasts that the company will post earnings of $1.47 per share for the year. The consensus estimate for Neumora Therapeutics’ current full-year earnings is ($1.61) per share.

NMRA has been the topic of several other reports. HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Neumora Therapeutics in a research note on Friday. Needham & Company LLC reiterated a “buy” rating and set a $23.00 price target on shares of Neumora Therapeutics in a report on Thursday, January 2nd. Bank of America decreased their price objective on shares of Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating for the company in a research note on Monday. Royal Bank of Canada downgraded Neumora Therapeutics from an “outperform” rating to a “sector perform” rating and cut their price objective for the company from $29.00 to $4.00 in a research report on Thursday, January 2nd. Finally, JPMorgan Chase & Co. downgraded Neumora Therapeutics from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $18.00 to $15.00 in a research report on Tuesday, November 5th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $16.50.

Neumora Therapeutics Stock Up 14.3 %

Shares of NASDAQ:NMRA opened at $2.48 on Monday. The firm has a fifty day simple moving average of $10.28 and a two-hundred day simple moving average of $11.46. Neumora Therapeutics has a 52 week low of $1.83 and a 52 week high of $21.00. The stock has a market capitalization of $400.67 million, a P/E ratio of -1.33 and a beta of 2.71.

Neumora Therapeutics (NASDAQ:NMRA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). During the same period in the previous year, the company posted ($1.14) EPS.

Insiders Place Their Bets

In other Neumora Therapeutics news, insider Robert A. Lenz sold 5,563 shares of the firm’s stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $15.01, for a total transaction of $83,500.63. Following the transaction, the insider now owns 322,966 shares of the company’s stock, valued at approximately $4,847,719.66. This trade represents a 1.69 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Matthew K. Fust sold 14,049 shares of the business’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $17.03, for a total transaction of $239,254.47. Following the completion of the sale, the director now owns 20,100 shares of the company’s stock, valued at approximately $342,303. This represents a 41.14 % decrease in their position. The disclosure for this sale can be found here. 26.40% of the stock is currently owned by company insiders.

Institutional Trading of Neumora Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of NMRA. Geode Capital Management LLC lifted its stake in shares of Neumora Therapeutics by 54.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,979,847 shares of the company’s stock worth $26,159,000 after purchasing an additional 694,385 shares during the last quarter. Barclays PLC lifted its position in shares of Neumora Therapeutics by 352.9% during the third quarter. Barclays PLC now owns 129,210 shares of the company’s stock valued at $1,708,000 after buying an additional 100,678 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Neumora Therapeutics by 139.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 698,255 shares of the company’s stock valued at $9,224,000 after buying an additional 406,891 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Neumora Therapeutics in the 3rd quarter valued at about $1,097,000. Finally, Callan Capital LLC grew its position in shares of Neumora Therapeutics by 222.6% in the 2nd quarter. Callan Capital LLC now owns 661,194 shares of the company’s stock worth $6,500,000 after buying an additional 456,207 shares during the last quarter. Institutional investors own 47.65% of the company’s stock.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.